Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings Inc (PETV) is a pioneering developer of biomedical devices for veterinary care, specializing in innovative solutions for animal joint health. This dedicated news hub provides investors and industry professionals with timely access to all official company announcements and press releases.
Track PetVivo's latest developments including product innovations like Spryng™ with OsteoCushion™ Technology, financial performance updates, and strategic partnerships. Our curated collection ensures stakeholders stay informed about regulatory milestones, clinical advancements, and market expansions in the pet therapeutics sector.
This resource serves as a centralized repository for critical updates affecting investment decisions and industry analysis. Users gain efficient access to verified information on licensing agreements, manufacturing developments, and subsidiary activities across PetVivo's operational network.
Bookmark this page for streamlined monitoring of PetVivo's progress in transforming veterinary medicine through adapted human medical technologies. Regularly updated to reflect the company's evolving position in the biomedical devices landscape.
PetVivo Holdings raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ as Spryng™ and initiating sales. In Q2 2022, revenue reached $4,977, up from $4,790 in Q2 2021. The company reported a net loss of $1,105,474, improved from $1,348,002 in the same period last year. For the six months ended September 30, 2021, revenue was $9,122. The company aims to utilize offering proceeds to enhance sales and marketing efforts and has made key management hires.
PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ to Spryng™. As of September 30, 2021, revenues increased to $4,977 for Q2 2021 from $4,790 in Q2 2020. Net loss decreased to ($1,105,474) compared to ($1,348,002) year-over-year. Significant investments in sales, marketing, and research were made to support the launch of Spryng™. Key management hires were also announced.
PetVivo Holdings, Inc. will release its financial results for Q2 FY 2022 on November 15, 2021, post-market. A conference call is scheduled for 4:00 p.m. CT to discuss these results. The call will be available via webcast on their Investor Relations website. PetVivo focuses on innovative medical devices for animals, leveraging human therapies to expedite market entry. They have a pipeline of 17 products and 21 patents, with their lead product, SPRYNG™, aimed at treating osteoarthritis in dogs and horses, set for expanded sales this quarter.
PetVivo Holdings, Inc. (NASDAQ: PETV) has appointed Kick as its advertising agency to enhance its branding and marketing strategies. Kick, known for its extensive experience in the animal industry, will assist PetVivo in advertising, digital media, and experiential marketing. CEO John Lai emphasized Kick's strong commitment to impactful messaging and innovative solutions. PetVivo is focused on developing therapeutic devices for animals, notably its flagship product, Spryng with OsteoCushion Technology, aimed at treating osteoarthritis in companion animals, set for expanded commercialization in Q4 2021.
PetVivo Holdings, Inc. (NASDAQ: PETV) has appointed Joe Manning, DVM, as Senior Technical Veterinarian. Dr. Manning, with over 30 years in the veterinary field, is expected to enhance product development and commercialization of PetVivo's therapeutics for animals. His expertise includes a strong background in marketing and sales for veterinary products. The company aims to leverage human therapies for animal treatment, aiming for accelerated market entry compared to traditional pharmaceuticals. Their lead product, SPRYNG™, will see expanded commercial sales in Q4 2021.
New to The Street will air a special broadcast on September 25, 2021, at 6 PM EDT featuring GlobeX Data (OTCQB:SWISF) and PetVivo (NASDAQ:PETV). The show will reach over 227 million homes across various regions including the US, Latin America, MENA, Asia Pacific, and Australia. Additionally, FMW Media operates one of the longest-running TV brands, enhancing visibility for featured companies. PetVivo focuses on innovative biomedical devices for pets, aiming to leverage advancements from the human medical sector for quicker market entry.
PetVivo Holdings (NASDAQ: PETV) invites investors to its live presentation on September 29, 2021, at the Emerging Growth Conference. The event will feature CEO John Lai discussing the company's innovative medical therapeutics for pets, including their lead product, spryng™ with OsteoCushion™ Technology. Attendees will have the opportunity to ask questions directly during the session starting at 12:00 PM ET. For those unable to attend, an archived webcast will be available later.
PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of Josh Wilhelm as the new Director of Manufacturing. Wilhelm brings expertise in cGMP manufacturing and process engineering, previously serving at the Schulze Diabetes Institute. He aims to enhance the production of spryng, a therapeutic product for treating arthritis in companion animals. The company focuses on innovative medical devices for pets, with a pipeline of 17 products and 21 patents. spryng is expected to expand its commercial availability later this year.
PetVivo Holdings, Inc. (NASDAQ: PETV) announced Mark Middleton as the new National Director of Sales. His 38 years of experience in the Animal Health Industry, including leadership roles at Animal Health International, is expected to enhance sales of PetVivo's spryng™ product, which utilizes OsteoCushion Technology for treating osteoarthritis in pets. The company aims to accelerate revenue generation by leveraging innovative medical therapeutics for companion animals. The lead product is set for expanded commercial sale later this year.
FAQ
What is the current stock price of Petvivo Hldgs (PETV)?
What is the market cap of Petvivo Hldgs (PETV)?
